secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2026-07-28T12:20:37+00:00
Accession:  0001140361-26-029841
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools sells Mass Cytometry business to Multiplex Bio, receives $30M from Illumina buyout
--------------------------------------------------------------------------------

- Sells Mass Cytometry business (CyTOF/Hyperion) to Multiplex Bio for up to $10M; provides up to $10M working capital loan.
- Received ~$30M cash from Illumina to waive 2026 earnout and terminate royalty/license agreements from SomaLogic acquisition.
- Early termination of HSR waiting period for Treeline merger; merger expected to close by end of 2026.
- Multiplex Bio led by industry veterans; business to continue under Standard BioTools brand.
- Transactions subject to stockholder approval and customary conditions; expected to close concurrently with Treeline merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000114036126029841/0001140361-26-029841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000114036126029841/ef20078901_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-029841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer